Assessing the efficacy of darolutamide in metastatic hormone-sensitive prostate cancer based on subgroup meta-analysis and reconstructed individual patient data

Abstract Background Recently published phase III clinical trials documented that darolutamide could improve the prognosis of patients with metastatic hormone-sensitive prostate cancer (mHSPC). This meta-analysis aims to assess the efficacy of darolutamide in mHSPC based on subgroups and reconstructe...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fuxun Zhang, Zhirong Luo, Qi Xue, Xuyan Guo, Qiang Fu, Wei Zhang, Yang Xiong, Pati-Alam Alisha, Uzoamaka Adaobi Okoli, Geng Zhang, Yong Jiao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Springer 2025-11-01
Edice:	Discover Oncology
Témata:	Prostate cancer Androgen deprivation therapy Darolutamide Prognosis Outcome.
On-line přístup:	https://doi.org/10.1007/s12672-025-03875-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!